Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs

Gain Therapeutics Inc GANX has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs.
These results were highlighted at the International Conference on Alzheimer's (AD) and Parkinson's Diseases (PD).
The data shows that improving the lysosomal function through enhanced glucocerebrosidase (GCase) levels and activity can improve key pathological features in α-synucleinopathies and AD.
Related: Gain Therapeutics Stock Surges On Positive Preclinical Readout For Neurodegenerative Disease Drugs.
Orally bioavailable and brain-penetrant lead structurally targeted allosteric regulators (STARs) reduce neurotoxicity derived from the accumulation of toxic oligomeric species of Aβ and α-synuclein.
In mouse models, treatment with the STAR small molecule resulted in a decrease in neurotoxicity, motor deficit, neuroinflammation, and increase of neuronal survival.
Price Action: GANX shares are up 3.94% at $3.43 during the market session on the last check Tuesday.